Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.46 |
| ▸ | DRD3 | P35462 | 9/20 | 0.46 |
| ▸ | DRD4 | P21917 | 7/20 | 0.46 |
| ▸ | DRD1 | P21728 | 5/20 | 0.46 |
| ▸ | DRD5 | P21918 | 5/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTR5A | P47898 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019743 | 1.00 | DRD2 (0.46) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL3023895 | 1.00 | DRD2 (0.46) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL3020753 | 0.88 | DRD2 (0.48) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL3018279 | 0.85 | PDE4B (0.47) | RORCKDM4EPDE4B | |
| SCHEMBL3018278 | 0.85 | PDE4B (0.47) | RORCKDM4EPDE4B | |
| SCHEMBL3024378 | 0.83 | RORC (0.43) | RORCTACR1KDM4EPDE4B | |
| SCHEMBL3023828 | 0.83 | RORC (0.43) | RORCTACR1KDM4EPDE4B | |
| SCHEMBL3023830 | 0.83 | RORC (0.43) | RORCTACR1KDM4EPDE4B | |
| SCHEMBL3024958 | 0.83 | RORC (0.43) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL3024960 | 0.83 | RORC (0.43) | DRD2DRD3DRD4DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR2C, TPH2 | DRD2 30/4885DRD3 54/4885DRD4 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.